Background/Objectives: Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global health challenge, exacerbated by the emergence of multidrug-resistant strains and limited efficacy of existing therapies. Given the involvement of multiple essential mycobacterial proteins, multitarget drug discovery represents a rational therapeutic strategy. Methods: In this study, an integrated in silico pipeline combining machine learning–based quantitative structure–activity relationship modeling, graph neural network–driven drug–target affinity prediction, molecular docking, molecular dynamics (MD) simulations, and pharmacokinetic–toxicity profiling was employed to identify potential antitubercular leads from natural products. Results: A curated library of over 0.69 million compounds from the COCONUT database was systematically screened against seven essential M. tuberculosis protein targets. Machine learning and heterogeneous graph neural network models effectively captured complex ligand–protein interaction patterns, enabling high-confidence multitarget prioritization. Structure-based docking and MM-GBSA analyses revealed favorable binding affinities, further supported by 100 ns Molecular Dynamics simulations demonstrating stable binding and conformational integrity. In silico ADMET and toxicity predictions identified pharmacokinetically balanced candidates, while density functional theory calculations corroborated favorable electronic properties. Conclusion: Notably, a myricetin-based flavonoid glycoside exhibited consistent multitarget binding and dynamic stability across all targets. Overall, this study underscores the potential of integrated artificial intelligence and structure-based approaches in accelerating natural product-based antitubercular drug discovery and supports further experimental validation of prioritized leads.
Periasamy et al. (Thu,) studied this question.